オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - fluoxetine hydrochloride, quantity: 22.4 mg (equivalent: fluoxetine, qty 20 mg) - capsule, hard - excipient ingredients: titanium dioxide; iron oxide yellow; dimeticone 350; gelatin; patent blue v; pregelatinised maize starch - treatment of major depression. treatment of obsessive compulsive disorder (ocd). treatment of major depression. treatment of obsessive compulsive disorder (ocd).

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - escitalopram oxalate, quantity: 25.54 mg (equivalent: escitalopram, qty 20 mg) - tablet, film coated - excipient ingredients: colloidal anhydrous silica; hypromellose; titanium dioxide; microcrystalline cellulose; macrogol 6000; purified talc; croscarmellose sodium; magnesium stearate; lactose monohydrate - treatment of major depression. treatment of obsessive compulsive disorder.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - escitalopram oxalate, quantity: 12.77 mg (equivalent: escitalopram, qty 10 mg) - tablet, film coated - excipient ingredients: colloidal anhydrous silica; purified talc; hypromellose; macrogol 6000; microcrystalline cellulose; croscarmellose sodium; magnesium stearate; lactose monohydrate; titanium dioxide - treatment of major depression. treatment of obsessive compulsive disorder.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - azathioprine, quantity: 50 mg - tablet, film coated - excipient ingredients: magnesium stearate; colloidal anhydrous silica; titanium dioxide; lactose monohydrate; maize starch; purified talc; povidone; hypromellose; microcrystalline cellulose; peg-8 stearate - immunosuppressant antimetabolite: either alone, or more commonly, in combination with other agents (usually corticosteroids) and procedures which influence the immune response. therapeutic effect may be evident only after weeks or months and can include a steroid-sparing effect, thereby reducing the toxicity associated with higher dosage and prolonged usage of corticosteroids. azathioprine, in combination with cortocosteroids and/or other immunosuppressive agents and procedures, is indicated in the management of patients receiving organ transplants. azathioprine, either alone or more usually in combination with corticosteroids and/or other procedures, has been used with clinical benefit which may include reduction of dosage or discontinuation of corticosteroids, in a proportion of patients suffering from the following: severe rheumatoid arthritis, systemic lupus erythematosus, dermatomyositis/polymyositis, autoimmune chronic active hepatitis, pemphigus vulgaris, polyarteritis nodosa, autoimmune haemolytic anaemia, chronic refractory idiopathic thrombocytopenic purpura.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - azathioprine, quantity: 25 mg - tablet, film coated - excipient ingredients: purified talc; lactose monohydrate; magnesium stearate; maize starch; povidone; colloidal anhydrous silica; titanium dioxide; hypromellose; microcrystalline cellulose; peg-8 stearate - immunosuppressant antimetabolite: either alone, or more commonly, in combination with other agents (usually corticosteroids) and procedures which influence the immune response. therapeutic effect may be evident only after weeks or months and can include a steroid-sparing effect, thereby reducing the toxicity associated with higher dosage and prolonged usage of corticosteroids. azathioprine, in combination with cortocosteroids and/or other immunosuppressive agents and procedures, is indicated in the management of patients receiving organ transplants. azathioprine, either alone or more usually in combination with corticosteroids and/or other procedures, has been used with clinical benefit which may include reduction of dosage or discontinuation of corticosteroids, in a proportion of patients suffering from the following: severe rheumatoid arthritis, systemic lupus erythematosus, dermatomyositis/polymyositis, autoimmune chronic active hepatitis, pemphigus vulgaris, polyarteritis nodosa, autoimmune haemolytic anaemia, chronic refractory idiopathic thrombocytopenic purpura.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - amoxicillin trihydrate (equivalent: amoxicillin, qty mg) - capsule, hard - excipient ingredients: microcrystalline cellulose; magnesium stearate; iron oxide yellow; titanium dioxide; gelatin - treatment of the following infections due to susceptible strains of sensitive organisms: note: therapy should be guided by bacteriological studies, including sensitivity tests, and by clinical response. amoxicillin alone or in combination with another antibiotic, may be used in an emergency where the causative has not been identified. ? respiratory tract infections (acute and chronic): h. influenzae; streptococcus; s. pneumoniae; staphylococcus, nonpenicillinase producing; e. coli (see microbiology). ? urogenital infections (complicated and uncomplicated, acute and chronic): e. coli (see microbiology), p. mirabilis and strep. faecalis. ? gonorrhoea: n. gonorrhoea (nonpencillinase producing). ? skin and skin structure infections: staphylococcus, nonpenicillinase producing; streptococcus; e. coli (see microbiology). ? prophylaxis of endocarditis: amoxicillin may be used for the prophylaxis of bacterial endocarditis in individuals at particular risk, such as those with a prosthetic heart valve or those who have previously had endocarditis. infections caused by pathogens with established penicillin g susceptibility should preferentially be treated with penicillin g.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - metoprolol tartrate, quantity: 100 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; maize starch; crospovidone; colloidal anhydrous silica; microcrystalline cellulose; magnesium stearate; calcium hydrogen phosphate dihydrate; hyprolose - hypertension; angina pectoris; suspected or definite myocardial infarction; migraine prophylaxis.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - metoprolol tartrate, quantity: 50 mg - tablet, uncoated - excipient ingredients: colloidal anhydrous silica; maize starch; calcium hydrogen phosphate dihydrate; lactose monohydrate; crospovidone; hyprolose; magnesium stearate; microcrystalline cellulose - hypertension; angina pectoris; suspected or definite myocardial infarction; migraine prophylaxis

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - valaciclovir hydrochloride hydrate, quantity: 556.275 mg (equivalent: valaciclovir, qty 500 mg) - tablet, film coated - excipient ingredients: crospovidone; magnesium stearate; povidone; microcrystalline cellulose; titanium dioxide; hypromellose; polysorbate 80; macrogol 400 - for the treatment of herpes zoster (shingles) in adult patients who commence therapy within 72 hours of the onset of rash. for the treatment of ophthalmic zoster. for the treatment of clinical episodes of genital herpes simplex infections. for the prevention of recurrent genital herpes in immunocompromised patients with creatinine clearance of >15ml/min. prophylaxis of cytomegalovirus (cmv) infection and disease following solid organ transplantation in patients at risk of cmv disease.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - citalopram hydrobromide, quantity: 49.98 mg (equivalent: citalopram, qty 40 mg) - tablet, film coated - excipient ingredients: sodium starch glycollate; hypromellose; maize starch; lactose monohydrate; purified talc; microcrystalline cellulose; glycerol; macrogol 6000; magnesium stearate; titanium dioxide; copovidone - treatment of major depression.